Stay updated with breaking news from Gen Pharma Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target cut by Oppenheimer from $34.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $54.00 target price on shares of UroGen Pharma […]
UroGen Pharma (NASDAQ:URGN – Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, March 14th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. UroGen Pharma Trading Down […]
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) insider Mark Schoenberg sold 3,789 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $59,638.86. Following the sale, the insider now directly owns 149,423 shares of the […]
Clal Insurance Enterprises Holdings Ltd lessened its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 58.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 222,159 shares of the company’s stock after selling 307,229 shares during the quarter. Clal Insurance Enterprises Holdings […]
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 3,550,000 shares, a growth of 15.6% from the December 15th total of 3,070,000 shares. Based on an average trading volume of 263,700 shares, the short-interest ratio is currently 13.5 […]